<DOC>
	<DOCNO>NCT02279615</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy combination therapy involve β3-adrenoceptor agonist , mirabegron , α-blockers treatment OAB symptom male patient BPH .</brief_summary>
	<brief_title>Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia .</brief_title>
	<detailed_description>Mirabegron ( MyrbetriqTM , Astellas Pharma Inc. ) drug approve FDA treatment overactive bladder ( OAB ) symptoms urinary frequency , urgency urgency incontinence . Multiple study show drug also potential improve patient tolerability , compliance subsequent patient quality life without induce unfavourable adverse event commonly associate antimuscarinic medication . These adverse event include , limited , dry mouth , constipation , confusion , acute urinary retention ( AUR ) . Studies show mirabegron may also provide effective treatment option OAB men benign prostatic hyperplasia ( BPH ) without induce mentioned adverse event . This study look combination therapy Mirabegron Tamsulosin , versus Tamsulosin placebo alone prove treatment ( Mirabegron Tamsulosin ) effective men suffer overactive bladder along benign prostatic hyperplasia .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Male patient age 50 Clinical BPH stable dose alphablocker therapy 1 month OAB symptom ( frequency , urgency , nocturia , urgency incontinence ) Postvoid residual ( PVR ) &gt; 200mL Active , cultureproven urinary tract infection Acute/chronic prostatitis Previous low urinary tract malignancy ( i.e . bladder , prostate malignancy ) History cystolithiasis Previous pelvic surgery ( i.e . prostatectomy , cystectomy , recent pelvic/endourologic instrumentation include cystoscopy , nephroscopy , ureteral stent insertion , Transrectal Ultrasound ( TRUS ) biopsy ) Previous pelvic radiation</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Benign Prostatic Hyperplasia</keyword>
	<keyword>Combination Therapy</keyword>
	<keyword>β3-Adrenoceptor Agonist</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>Myrbetriq</keyword>
	<keyword>α-Adrenoceptor Antagonist</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Flomax</keyword>
</DOC>